HUTCHMED (China) (NasdaqGS:HCM) Update / Briefing October 31, 2025 08:00 AM ET Speaker0Hello, everyone. Good evening and good morning. Thank you for joining the HUTCHMED 2025 R&D Day event. For your reference, you can go to our website to download today's presentation slides. The performance and results of operations of the HUTCHMED group contained within this presentation are historical in nature, and the past performance is no guarantee of future results. As usual, we will have a Q&A session at the end wh ...

Core Insights - The presentation focuses on the additional results from the Phase III VIKTORIA-1 clinical trial, specifically for the PIK3CA wild-type cohort, which were recently presented at the ESMO Congress in Berlin [1]. Group 1: Company Overview - Celcuity is led by CEO and Co-Founder Brian Sullivan, who is joined by Chief Medical Officer Dr. Igor Gorbatchevsky for the presentation [1]. Group 2: Clinical Trial Details - The VIKTORIA-1 trial is significant as it explores the PAM pathway, which is a crucial oncogenic pathway involving PI3K, AKT, and mTOR [3].